Vaccination is a crucial approach to eradicate and control a myriad of infectious and non-communicable diseases. Subunit vaccines are considered the most convenient approach for vaccine formulation; however, the development of new adjuvants and vaccine delivery vehicles to improve the immunogenicity of such formulations is needed. The authors of this review describe the recent application of porous silicon particles (PSiP) as both a potential vaccine delivery vehicle and adjuvant. PSiP are attractive for this application due to its safety, biodegradability and compatibility for functionalization. Herein, the development of multi-epitope cancer vaccines is discussed as an example on how PSiP are promising materials for the development of innovative vaccines.
Introduction
Vaccination is a key invention for the biomedical field that had saved millions of deaths primarily associated to infectious diseases (WHO, 2016) . In addition, vaccination against non-infectious diseases (e.g. cancer) is acquiring a great relevance. Multi-epitope vaccines are considered a relevant trend in vaccinology, since they comprise a set of specific protective epitopes and may achieve broad im-munoprotective responses (Jafarpour et al., 2015) . This is especially important for pathologies requiring wide immune responses against multiple targets to successfully combat the pathogen or malignant cells. A common approach for the formulation of such vaccines is based in mixtures of synthetic peptides; however, they tend to be poorly immunogenic. The use of chimeric recombinant proteins is an alternative to synthetic peptides with the advantage that they can be produced in recombinant organisms at the large scale and in general at a lower cost (Durántez et al., 2009 ). Nevertheless, the design of functional chimeric proteins faces the following challenges: 1) to achieve adequate expression of the protein in the host; 2) to retain the immunogenic properties of the individual epitopes and 3) to fulfill the uptake and processing by the antigen presenting cells (APC) and induce a proper immune response in terms of polarization and potency (Rosa et al., 2015) .
Another approach to achieve the production of a highly immunogenic vaccine consists in the use of adjuvants, which enhance the immune response and influence immune polarization (Hirayama and Nishimura, 2016) . The polarization of the immune system arms towards humoral or cytotoxic T cell responses is typically required to achieve immunoprotection to a specific pathology (Roitt et al., 2008) . Although there are several adjuvants with proved efficacy such as Toll-like receptor (TLR) ligands (e.g. CpGs), bacterial toxins, silver salts, and interleukins (e.g. IL-12); common limitations in this group include high production cost and adverse effects (Apostólico et al., 2016; Reed et al., 2016) . In addition, some peptides can exert adjuvant effects; for instance, the pan HLA DRbinding epitope (PADRE) is a peptide sequence that actives T helper lymphocytes (Th) and has been used and validated as an adjuvant in several vaccine formulations (Alexander et al., 1994; Jafarpour et al., 2015; Shukla et al., 2016; Juárez et al., 2016) .
Moreover, a crucial need in vaccinology is the development of vaccines administered by attractive administration routes, such as the oral route; that allows an easy and painless administration not requiring sterile devices and trained personnel (Juárez et al., 2016) . However, the induction of strong immune responses by oral vaccination is a challenge due to the tolerogenic nature of the gut associated lymphoid tissues (GALT), and the low antigen bioavailability derived from the antigen dilution and degradation in the gastrointestinal tract (Burbank et al., 2016) . To address this challenge, several strategies have been explored to enhance the efficacy of oral vaccine formulations. For instance, the use of novel delivery vehicles has been assessed since they can increase antigen stability, particularly when it is administered by mucosal routes; and it can also activate mechanisms of the innate immunity, such as the antigen uptake and cytokine production by the APC (Xia et al., 2015) . Therefore, the use of delivery vehicles could influence not only the potency but also the type of immune response (cellular or humoral).
Among the vaccine delivery vehicles assessed thus far, liposomes (Conniot et Among the solid nanoparticles used as delivery vehicles of vaccines, the following materials have been evaluated: polylactic acid (PLA), polyethylene glycol (PEG), poly(lactic-co-glycolic acid) (PLGA), chitosan, gold, silica and silicon (Salazar-González et al., 2015; Lin et al., 2015; Navarro-Tovar et al., 2016). This review is focused in the potential use of PSiP that may serve as delivery vehicles and adjuvants in vaccinology. A brief description of the synthesis and properties of PSiP is provided and the potential applications on vaccinology are discussed.
Nanoparticles as delivery vehicle in vaccines
Given the current challenges in vaccinology, new materials for obtaining formulations with the ability to attain proper immunogenicity and immune polarization are a need in the field. For instance, the immunity mediated by cytotoxic lymphocytes (Th1) plays a crucial role in the defense against cancer and intracellular pathogens. Since the induction of Th1 responses depends on the activation of components of the innate immune response leading to the production of specific cytokines and the type of antigen presentation into the APC, carriers or adjuvants that activate or influence such mechanisms have been explored (Bedoui et al., 2016) . For more than a decade, nanoparticles have been applied for this purpose. A diverse group of nanoparticles varying in the nature of the material, shape, and size has been generated offering a myriad of possibilities for vaccine design. The efficacy of such particles is in part explained by their capability of being internalized by the APC through different mechanisms (Gregory et al., 2013) . The main factors that affect the immunostimulatory function of the nanoparticle comprise their size, shape and surface characteristics (Bachmann and Jennings, 2010) . Therefore, nanomaterials can be optimized to achieve a proper uptake by APC with the subsequent delivery, processing and presentation of the antigen to lymphocytes (Paulis et al., 2013) . In this scenario, an example is the use of nanocrystals and adjuvants based on aluminum salts, which are co-administered along with the antigen activating the inflammasome and promoting IL-1β production by dendritic cells (DC), therefore enhancing antigen presentation and strengthening the induced immune response (Sharp et al., 2009 
Synthesis and Properties of PSiP

Approaches for active biomolecule loading onto PSiP
There are different approaches to formulate nanoparticlebased delivery systems: (1) adsorption onto the particle surface; (2) chemical conjugation; and (3) encapsulation (Navarro-Tovar et al., 2016). Particularly, for PSiP only the first two approaches are achievable (since the material is not a capsule). In some applications loading may not be necessary; this is the case for vaccine formulations with PSiP along with antigens, in which the co-administered PSiP may exert an adjuvant effect not requiring specific interactions with the antigen (Seth et al., 2015) . In this section, a brief description of each loading method is provided, emphasizing the PSiP cases.
Peptide Adsorption onto the particle surface
The simplest experimental method to load an active biomolecule, such as enzymes, antibodies or antigens, is placing directly the biomolecule and particles in a solution under specific pH and temperature. In the vaccinology area, it is well described by several authors that the range of antigenic peptides loading varies from ∼4 to 30% depending on the testing system (Kaasalainen et al. . The direct biomolecule-PSiP interaction is a physical type of interaction, which involves intermolecular forces. In this regard, the isoelectric point (PI) of PSiP is reported as 4.5 (Kaasalainen et al., 2015) . Therefore, for most of the biological applications where the physiological pH is 7.34, the PSiP surface is negatively charged (Si-O − x ). Thus, a direct interaction between a molecule, such as peptides, and PSiP surface at pH = 7.34 requires positively charged biomolecules (with a PI > 7.34) for strong intermolecular forces (electrostatic forces). Additionally, the interactions between biomolecules and PSiP surface could be through van der Waals forces between non-charged re-gions on the particle surface (Si-Si and Si-Hx) and nonpolar regions of the biomolecule.
On the other hand, a negatively charged biomolecule at physiological pH (PI < 7.34) is unable to interact with the negatively charged PSiP by electrostatic forces. Then, to assure a strong interaction, the porous material can be functionalized with organic molecules to turn its negative charge into a positive charge. The most common organosilane used for silica and silicon nanoparticle functionalization is 3-aminopropyltriethoxysilane (APTES) (see Figure 1) , which possesses three hydrophobic chains that interact with the surface of the inorganic material. The fourth chain of APTES has an NH 2 -terminal exposed onto the surface and it is easily charged at physiological conditions (Navarro-Tovar et al. Other surface modifications could be performed to achieve PSiP with hydrophobic surface. In this sense, the hydrosilylation involves the reaction of a terminal alkene or alkyne with Si-H bond under thermal, photochemical or Lewis acid catalysis. Moreover, the covalent binding of Grignard and alkyl reagents and also, the electrochemical oxidation of methyl-Grignard reactants are an alternative when hydrosilylations are not possible. Thus, the addition of alkyl chains to the structure provides a hydrophobic region that also stabilizes the PSiP and facilitates the loading of hydrophobic drugs and proteins (Anglin et al., 2008) .
The possible intermolecular forces between peptides and the silicon surface are discussed by Ramakrishnan et al. (2014) by an interesting modeling study on the interaction of various peptides onto a silicon surface, where electrostatic forces and interactions between non polar regions are determined by quantum mechanistic calculations (Ramakrishnan et al., 2014) .
It is important to mention at this point that none of the surface modifications have a 100% surface coverage, and experimental analysis have shown that remants of Si-H are present after modifications. However, the modifications offer high stability and increase the interaction with the biomolecules (Lee et al., 2003 ). Figure 1 ). It is reported that the biomolecule, also called payload, is only released in the biological system when the covalent bonds are broken or the PSiP is degraded. However, every single study must incorporate activity assays to ensure that the biomolecule retains its biological activity (Kilian et 
Chemical conjugation of a peptide onto the PSiP surface
Effects of PSiP in immune system cells
To the date, only preliminary reports regarding the use of PSiP to deliver antigens have been reported. In this aspect, a study reports the use of PSiP as a strategy to deliver antigens and enhance the antigen presentation through major histocompatibility complex class I (MHC-I) molecules 
Perspectives for PSiP use in cancer immunotherapy
Cancer is a medical terminology used for the groups of pathologies typified by the presence of abnormal cells characterized by alterations in the cell division control and the capability of invading other tissues as well as inducing angiogenesis (WHO, 2016). There are more than 100 types of cancers and any part of the body can be affected by this pathology. In 2008, 7.6 million people died of cancer, accounting for 13% of all deaths worldwide. The most common therapies against cancer are surgery, chemotherapy and radiotherapy. However, these thera-pies are limited due to their low specificity and/or ineffectiveness for the control of the minimal residual disease (Subiza et al., 1994) . It is known that the immune system plays a key role on the vigilance and destruction of malignant cells. Nonetheless, the malignant cells also possess mechanisms to evade the immune system (Duharte, 2003) . Two relevant TAAs that exemplify such wide group of molecules are the receptor tyrosine-protein kinase erbB-2 (HER2/neu/ErbB2) and Wilms tumor protein (WT1), which are associated to therapeutic effects against several cancer types. HER2/neu/ErbB2 is a 185 kDa membrane glycoprotein, which belongs to the ErbB2 family that groups the EGFR 1 (HER1), HER3 and HER4 receptors (Yarden and Sliwkowski, 2001 ). Despite the HER2 does not possess a specific ligand, it is an important inductor of a heterodimerization process that leads to transduction of several signals that promote mitosis, apoptosis, angiogenesis and cellular differentiation. The extracellular domain of HER2 comprises 630 amino acids in four domains (I-IV). It is known that the dimerization loop in domain II is permanently exposed. This could explain the predominant role of HER2 from its family receptors in the dimerization process (Menard et al., 2000) .
The company Genentech Inc. (San Francisco, CA) developed the most known therapy against HER2. The commercial drug is Herceptin, which is constituted by a monoclonal antibody called Trastuzumab. Herceptin increases the survival rate (Popat and Smith, 2008) and it has been proven as the first treatment election in patients diagnosed with HER2 positive breast cancer and metastasis. Trastuzumab targets the terminal portion of the domain IV, where the binding site with the loop II of HER1 and HER3 receptors is located (Cho et al., 2003) . However, the therapies based in passive immunity have limitations. This is the case of Trastuzumab, for which most of the treated patients have a positive initial response; however a subsequent progression of the cancer is frequently observed (Nahta et al., 2006) . Therefore, major efforts are needed to improve the efficacy of immunotherapies. In this sense, the use of monoclonal antibodies against different TAAs (Sharon et al. 2005 ) has been proposed as well as the use of antibody-mimicking agents targeting several epitopes (Nahta et al., 2006; Pal and Pegram, 2007) .
On the other hand, WT1 was described from etiologic studies of Wilms tumor, a type of renal paediatric cancer. This protein is a transcription factor carrying zinc fingers, and is involved in the regulation of proliferation, cellular differentiation, apoptosis and organs development (Drummond et al. Considering that passive immunotherapies require frequent dosage and are highly expensive, active immunization is considered the ideal approach to direct the immune system against cancer. Despite the extensive knowledge on these targets, the challenges in cancer vaccinology are achieving immune responses whose potency and broadness led to cancer remission. This requires not only defining the proper combination of targets but also developing formulations with appropriate carriers/adjuvants that enhance the immune response and favor the desired Th-response polarization (Tagliamonte et al., 2014) . There is still a need to develop effective immunotherapies targeting several TAAs to achieve synergic immune responses (cellular and humoral) leading to improved efficacy (Pal y Pegram, 2006) . Vaccine formulations containing a mix of multiple synthetic peptides offer opportunities to target several TAAs at lower costs.
In this context, the perspective of using PSiP for the delivery of TAAs (such as synthetic peptides or multiepitopic proteins) is of great relevance for the field. The avenues to be explored could include: (i) evaluating the effi-cacy of PSiP for promoting the induction of CTL responses; (ii) assessing the efficacy of formulations of multicomponent vaccines comprising peptides from several TAAs along with adjuvant peptides. Since peptides vary in their physicochemical properties, it is proposed a methodology comprising individual adsorption/conjugation reactions under the corresponding optimal conditions followed by mixing the different PSiP-peptide complexes in a single formulation; (iii) the design of hybrid peptides carrying sequences from TAAs along with PSiP binding peptides; (iv) studying the adjuvant effect of the co-administration of TAAs and PSiP and (v) performing loading optimization studies for TAAs by testing the effects of concentration, pH and temperature.
Concluding remarks
Nanotechnology is opening new avenues for improving the vaccine development field. Surprisingly, PSiP have been narrowly explored for vaccination despite their advantageous characteristics in terms of safety, versatility for functionalization, adjuvant effects, and stability. Then, multi-target vaccines based in the use of PSiP as carriers represent a key future prospect for vaccinology. Research efforts in such directions will have a positive impact in the development of vaccines, particularly those requiring strong cellular responses, such as cancer and infections caused by intracellular pathogens, for which a limited number of effective adjuvants are in advanced developmental stages. 
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